SEC Form 4

Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average bu	urden
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL O	WNERSHIP
--------------------------------------	----------

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] STARKS DANIEL J				2. Issuer Name and Ticker or Trading Symbol <u>ABBOTT LABORATORIES</u> [ABT]							tionship of Repo all applicable) Director		to Issuer % Owner		
(Last)	(First)	(Middle		3. Date of Earliest Transaction (Month/Day/Year) 10/26/2023							Officer (give tit below)		her (specify low)		
100 ABBOTT		4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)										Х	Form filed by 0	One Reporting	Person		
ABBOTT PARK	IL	60064	4								Form filed by N Person	More than One	Reporting		
(City)	(State)	(Zip)		Rule 10b5-1(c) Transaction Indication X Check this box to indicate that a transaction was made pursuant satisfy the affirmative defense conditions of Rule 10b5-1(c). See						It to a contract, instruction or written plan that is intended to 9 Instruction 10.					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year			ate	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8) Code				tr. 3, 4 and 5) Si Bi O Fi R Ti	Amount of ecurities eneficially wned ollowing eported ransaction(s) nstr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		

26,907

23,093

D

D

\$93.8141⁽¹⁾

\$94.326⁽²⁾

6,748,409

6,725,316

D

D

Alynne Starks

Common shares without par value												258	3(3)]	In	12 revocable ust
		Tal	ble II - Derivati (e.g., pt						posed of, convertil				d			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Security or Exercise (Month/Day/Year) if any		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) Code (Instr. 4. 5. Numbe of Derivative Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		vative rities hired r osed) r. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivative Securitie Beneficia Owned Following Reported	derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
	n of Respons			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					

S

s

Explanation of Responses:

Common shares without par value

Common shares without par value

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$93.06 to \$94.05, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$94.06 to \$94.72, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.

<u>/s/</u>	Danie	<u>l J. </u>	Starks	<u>by :</u>	<u>Jessica</u>	10/20/2022
	n 11			~		10/30/2023

<u>H. Paik, Attorney-in-Fact</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

10/26/2023

10/26/2023

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See